Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
1. A method of treating chronic uveitis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide, which has the following structure:
or a pharmaceutically acceptable salt, or solvate thereof.
2. A method of treating chronic uveitis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide, which has the following structure:
or a pharmaceutically acceptable salt, or solvate thereof, and a therapeutically effective amount of a second active ingredient.
3. The method of claim 2 , wherein the second active ingredient is cytokine, anti-cancer agent, cox-2 inhibitor, or a combination thereof.
4. The method of claim 2 , wherein the second active ingredient is oblimersen, melphalan, G-CSF, GM-CSF, EPO, topotecan, pentoxifylline, taxotere, irinotecan, a COX-2 inhibitor, ciprofloxacin, dexamethasone, doxorubicin, vincristine, IL 2, IFN, dacarbazine, Ara-C, vinorelbine, isotretinoin, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or a combination thereof.
5. The method of claim 1 or 2 , wherein the compound is enantiomerically pure.
6. The method according to claim 1 or 2 , wherein the compound is administered in an amount of from about 1 to about 10,000 mg per day.
7. The method of claim 6 , wherein the compound is administered in an amount of about 10, 25, 50, 100, 200 or 300 mg per day.
8. The method of claim 6 , wherein the compound is orally administered.
9. The method of claim 6 , wherein the compound is administered in a capsule.
10. The method of claim 9 , wherein the compound is administered in 50 mg or 100 mg of a capsule.
11. The method of claim 6 , wherein the compound is topically administered.
12. The method of claim 11 , wherein the compound is administered in a spray, aerosol, solution, suspension or eye drop.
13. The method of claim 3 , wherein the second active ingredient is prednisone.